Innovation Article contributed by Carla Smith, Executive Vice President of The Healthcare Information and Management Systems Society (HIMSS) for PharmaBoardroom. We must assertively bend the arc of technology towards our patients, clinicians, researchers, and caregivers, and re-humanise the health system. One of the many ways patients are de-humanized in a health…

Medtech Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. He calls for healthcare to be given a new prescription. But, will the private sector write it?   The UK’s National Health Service has crippling sustainability challenges.   With many firms in the midst of or preparing for annual strategic planning sessions, it feels appropriate…

M&A It has been a robust first half in 2018 within the life sciences sector for mergers and acquisition (M&A) and investment activities. Deal-tracking sources demonstrate M&A values witnessed meaningful increases in Q2 2018, with deal volumes in the quarter reminiscent of 2016 and 2017 levels [1]. I and others [234] continue…

regulation The stakes are high, and the outcome is uncertain in one of the largest Pharma M&A deals ever. Takeda’s proposed acquisition of Shire seems to have it all: The combined entity becoming one of the largest global Pharma groups, enabling Takeda to become a truly global operation and allowing Shire’s…

Innovation “Imagine a world where every single ingredient inside every single pharmaceutical you take is traced from start to finish.” We can all agree that the healthcare system in the United States is in dire need of an overhaul. Technological advances propel us into the 21st Century, but the way data…

Regulation In this exclusive interview, Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), defines ‘fair pricing’, gives the IFPMA’s take on so-called “cost-plus” pricing models, and talks about access to medicine in developing markets.   The innovative pharmaceutical industry seems to be under unprecedented pressure…

Diversity Ai Hua Ong, Company Group Chairman, Asia Pacific, The Janssen Pharmaceutical Companies of Johnson & Johnson.   There is a clear correlation between an inclusive culture and innovation Creating a diverse workforce and an inclusive culture is key to an organisation’s success in today’s and tomorrow’s world. Organisations large and…

R&D In my career, I’ve held senior roles in both the biopharma and diagnostics sectors. Working across different cost structures, different business issues, and different regulatory systems in different parts of the world. I was once challenged as a new CEO in diagnostics by a pharma analyst to explain why I…

Regulation Article contributed by Carla Smith, Executive Vice President of The Healthcare Information and Management Systems Society (HIMMS) for PharmaBoardroom. Today more Canadians are dying in this crisis than at the height of the HIV epidemic. Recognizing that we need to join forces to fight the opioid epidemics in both our nations, Canadians…

Cancer Turkey has one of the most revered Social Security Systems in the world, providing its citizens with free healthcare and access to a long list of innovative cancer drugs. However, with one of the youngest populations in Europe, the sustainability of the system is uncertain as its incredibly young population gets older…

Mexico Representatives of Olivares, one of the leading law firms in Mexico, explain the evolving status of cannabis and narcotics for medicinal use in the country. A new Bill authorizing the use of cannabis for medical treatments was passed by the Senate in December 2016, but there is still a long…